1521.HK Stock Analysis
15
Uncovered
Frontage Holdings Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania and currently employs 1,505 full-time employees. The company went IPO on 2019-05-30. The firm is a contract research organization (CRO) providing integrated, scientifically driven research, analytical and development services throughout the drug discovery and development process for pharmaceutical companies. Its segments include North America and the People’s Republic of China (PRC). Its North America segment, including laboratory testing, chemistry, manufacturing and control (CMC), preclinical research and chemistry services in the United States of America and Canada. Its PRC segment including laboratory testing, CMC, preclinical research, bioequivalence clinical and chemistry services in the PRC. Its preclinical research services consist of drug metabolism and pharmacokinetic (DMPK) services and safety and toxicology service, absorption, distribution, metabolism and excretion and compound screening services. Its services and solutions include drug candidate evaluation, product development, and testing services.